GAMMA Investing LLC Buys 436 Shares of Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY)

GAMMA Investing LLC boosted its stake in shares of Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) by 92.6% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 907 shares of the company’s stock after acquiring an additional 436 shares during the period. GAMMA Investing LLC’s holdings in Harmony Biosciences were worth $31,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Mirae Asset Global Investments Co. Ltd. grew its stake in Harmony Biosciences by 21.2% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,056 shares of the company’s stock worth $80,000 after buying an additional 360 shares in the last quarter. Profund Advisors LLC lifted its holdings in shares of Harmony Biosciences by 11.1% during the 2nd quarter. Profund Advisors LLC now owns 7,557 shares of the company’s stock worth $228,000 after acquiring an additional 758 shares during the period. CWM LLC boosted its position in shares of Harmony Biosciences by 111.7% during the 3rd quarter. CWM LLC now owns 1,469 shares of the company’s stock worth $59,000 after acquiring an additional 775 shares in the last quarter. AQR Capital Management LLC boosted its position in shares of Harmony Biosciences by 0.7% during the 2nd quarter. AQR Capital Management LLC now owns 154,345 shares of the company’s stock worth $4,657,000 after acquiring an additional 1,116 shares in the last quarter. Finally, Handelsbanken Fonder AB increased its stake in Harmony Biosciences by 15.3% in the third quarter. Handelsbanken Fonder AB now owns 11,300 shares of the company’s stock valued at $452,000 after acquiring an additional 1,500 shares during the last quarter. 86.23% of the stock is owned by institutional investors and hedge funds.

Harmony Biosciences Trading Down 0.1 %

NASDAQ:HRMY opened at $36.42 on Wednesday. Harmony Biosciences Holdings, Inc. has a 1 year low of $28.14 and a 1 year high of $41.61. The stock’s fifty day moving average price is $34.21 and its two-hundred day moving average price is $34.74. The company has a debt-to-equity ratio of 0.28, a current ratio of 3.24 and a quick ratio of 3.20. The company has a market cap of $2.08 billion, a P/E ratio of 17.26, a P/E/G ratio of 0.60 and a beta of 0.78.

Harmony Biosciences (NASDAQ:HRMY) last announced its quarterly earnings results on Tuesday, October 29th. The company reported $0.79 EPS for the quarter, beating the consensus estimate of $0.64 by $0.15. The firm had revenue of $186.00 million during the quarter, compared to the consensus estimate of $184.07 million. Harmony Biosciences had a net margin of 17.98% and a return on equity of 23.16%. The business’s quarterly revenue was up 16.0% compared to the same quarter last year. During the same period last year, the firm earned $0.63 EPS. As a group, analysts expect that Harmony Biosciences Holdings, Inc. will post 2.36 EPS for the current year.

Insider Buying and Selling

In other news, insider Jeffrey Dierks sold 21,496 shares of the firm’s stock in a transaction dated Tuesday, October 29th. The stock was sold at an average price of $40.47, for a total transaction of $869,943.12. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. 30.80% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

Several brokerages recently weighed in on HRMY. Needham & Company LLC restated a “buy” rating and set a $52.00 price objective on shares of Harmony Biosciences in a research report on Monday. Mizuho increased their target price on shares of Harmony Biosciences from $42.00 to $52.00 and gave the stock an “outperform” rating in a report on Thursday, October 10th. Oppenheimer reaffirmed an “outperform” rating and set a $59.00 price target (up from $56.00) on shares of Harmony Biosciences in a report on Wednesday, October 30th. HC Wainwright started coverage on shares of Harmony Biosciences in a research note on Tuesday, December 17th. They issued a “buy” rating and a $75.00 price objective for the company. Finally, Cantor Fitzgerald boosted their target price on shares of Harmony Biosciences from $51.00 to $58.00 and gave the stock an “overweight” rating in a research note on Wednesday, October 30th. Eight research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company presently has a consensus rating of “Buy” and an average price target of $55.00.

About Harmony Biosciences

Harmony Biosciences Holdings, Inc, a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy.